|
16 Jun 2023
|
RPG Life Sciences
|
BOB Capital Markets Ltd.
|
2442.40
|
|
918.40
(165.94%)
|
|
Not Rated
|
|
|
FY23 a milestone year with revenue/EBITDA of Rs 500mn/100mn; Naprosyn brand crossed Rs 500mn
|
|
18 Jan 2023
|
RPG Life Sciences
|
Chola Wealth Direct
|
2442.40
|
1100.00
|
852.20
(186.60%)
|
Target met |
Buy
|
|
|
|
|
16 Sep 2022
|
RPG Life Sciences
|
BOB Capital Markets Ltd.
|
2442.40
|
|
768.75
(217.71%)
|
|
Not Rated
|
|
|
EBITDA margin up 10ppt from FY19 levels to ~20% in FY22 as efforts to improve operational efficiency pay off
|
|
18 Jun 2021
|
RPG Life Sciences
|
BOB Capital Markets Ltd.
|
2442.40
|
|
446.85
(446.58%)
|
|
Not Rated
|
|
|
RPGL reported revenue growth, margin expansion and debt reduction in FY21 despite Covid-led disruptions in the acute portfolio
|
|
15 Jun 2018
|
RPG Life Sciences
|
IDBI Capital
|
2442.40
|
|
377.00
(547.85%)
|
|
Mgmt Note
|
|
|
We recently met the management of RPG Life sciences (RPG). RPG is primarily engaged in manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs or bulk actives). RPG specializes in therapeutic areas like nephrology, oncology, urology, gastroenterology, pain management and nutritionals. RPG enjoys a strong brand recognition in anti-diarrheal, antacid, iron-vitamin, and nephrology segments. Domestic formulation 19% revenue growth YoY RPG has its manufacturing facilities in 1) Maharashtra and 2) Gujarat. RPG continues to strive to be a dominant player in specialty by focusing on differentiated products....
|
|
23 Jan 2017
|
RPG Life Sciences
|
IDBI Capital
|
2442.40
|
|
484.75
(403.85%)
|
|
Mgmt Note
|
|
|
RPG Life Sciences Ltd (RPG), formally known as Searle India was incorporated in 1968 as a pharmaceuticals and agrochemicals business, however, divested the agrochemicals in 2001 and renamed as RPG Phamaceuticals Ltd, HQ in Mumbai which is primarily engaged in manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs or bulk actives). RPG specializes in therapeutic areas like nephrology, oncology gastroenterology, pain management and nutritionals. RPG is ranked 66th (Source: Pharmatrac) in the domestic formulations market and ranks among the top 5 Indian companies in the renal therapy segment. Domestic market accounts for ~67% of revenues while the main:specialty ratio is at 60:40. The company has...
|
|
19 Dec 2016
|
RPG Life Sciences
|
HDFC Securities
|
2442.40
|
545.00
|
493.25
(395.16%)
|
|
Buy
|
|
|
BUY RPG Life Sciences at CMP Rs.469 and add on Declines to Rs.435 - 408 for sequential target of Rs. 545, 658
|
|
27 Sep 2013
|
RPG Life Sciences
|
Ajcon Global
|
2442.40
|
100.00
|
60.70
(3923.72%)
|
Target met |
Buy
|
|
|
RPG Life Sciences Ltd. is an integrated Pharmaceutical Company operating in the domestic and international markets in the Branded Formulations, Global Generics, Synthetic and Fermentation API's space. The Company is a research based Pharmaceutical Company, producing a wide range of quality, affordable medicines and exports to Europe, Latin America, Canada and South East Asian Countries. In Q1FY14, the Company's turnover witnessed yoy growth of 15 percent to touch...
|